Last updated 16 days ago
A Study to Assess the Efficacy and Safety of BIIB059 (Litifilimab) in Participants With Active Subacute Cutaneous Lupus Erythematosus (SCLE) and/or Chronic Cutaneous Lupus Erythematosus (CCLE) With or Without Systemic Manifestations and Refractory and/or Intolerant to Antimalarial Therapy
474 patients around the world
Available in Argentina, Chile, Colombia, Brazil, Mexico
BIIB059 is a humanized immunoglobulin G1 (IgG1) monoclonal antibody targeting blood
dendritic cell antigen 2 and is being investigated for the potential treatment of
systemic lupus erythematosus and cutaneous lupus erythematosus.
Biogen
41Research sites
474Patients around the world
This study is for people with
Lupus
Cutaneous lupus erythematosus
Requirements for the patient
From 18 Years
All Gender
Medical requirements
Sites
Clínica Mayo de UMCB SRL
Recruiting
Instituto de Investigaciones Clínicas Tucumán
Recruiting
Centro de Investigaciones Metabólicas (CINME) S.A. - CABA, Buenos Aires
Clínica Adventista Belgrano - CABA - Buenos Aires
Recruiting
Centro Polivalente de Asistencia e Investigación Clínica - CER San Juan
Recruiting
Instituto de Investigaciones Clínicas Quilmes
Recruiting
Instituto de Reumatología Mendoza
Recruiting
Instituto CAICI - Rosario, Santa Fe
Recruiting
Centro de Investigaciones Médicas Mar del Plata SRL
Recruiting
Centro de Investigaciones Médicas Tucumán
Recruiting
StudyAMETHYST
SponsorBiogen
Study typeInterventional
Conditions
Cutaneous lupus erythematosus
Requirements
From 18 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT05531565
